CGC - Canopy Growth Corporation

NYSE - NYSE Delayed Price. Currency in USD
43.71
+0.94 (+2.20%)
At close: 4:00PM EDT

44.00 +0.30 (0.69%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Previous Close42.77
Open43.87
Bid44.15 x 800
Ask44.40 x 1100
Day's Range42.47 - 43.94
52 Week Range24.21 - 59.25
Volume5,717,833
Avg. Volume5,049,376
Market Cap15.126B
Beta (3Y Monthly)4.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Canopy Growth Corporation reports fourth quarter and fiscal 2019 results with annual sales of $226.3M
    PR Newswire43 minutes ago

    Canopy Growth Corporation reports fourth quarter and fiscal 2019 results with annual sales of $226.3M

    Achieved annual net revenue growth of 191% to $226.3 million . Generated $140.5 million of gross revenue from new Canadian recreational channel and $78.9 million in global medical sales. Fourth quarter ...

  • CNW Group13 hours ago

    /R E P E A T -- Canopy Growth announces shareholder approval in connection with the proposed acquisition of Acreage & provides update on American hemp and CBD operations/

    SMITHS FALLS, ON , June 19, 2019 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (WEED.TO) (CGC) is pleased to announce that, at a special meeting of the Company's shareholders (the "Meeting") held earlier today, the Company's shareholders voted overwhelmingly in favour of the resolution (the "Canopy Shareholder Resolution") approving the issuance of common shares of Canopy Growth and certain amendments to certain outstanding Company warrants in connection with the Company's previously announced proposed acquisition (the "Transaction") of Acreage Holdings, Inc. ("Acreage").

  • CNW Group2 days ago

    Canopy Rivers to Report Fourth Quarter and Fiscal Year 2019 Financial Results

    TORONTO , June 19, 2019 /CNW/ - Canopy Rivers Inc. (the "Company") (RIV.V) (CNPOF) will report its financial results for the fourth quarter and fiscal year ended March 31, 2019 before markets open on Tuesday, July 16, 2019 . The Company's audited consolidated financial statements and Management's Discussion and Analysis for the three and twelve months ended March 31, 2019 will be available on the Company's profile on SEDAR at www.sedar.com and in the Investors section of the Company's website at www.canopyrivers.com. Certain preliminary financial information pertaining to the Company may also be found in the financial results released by Canopy Growth Corporation (TSX: WEED, NYSE: CGC), which are currently scheduled to be released on June 20, 2019 .

  • CNW Group2 days ago

    Canopy Growth announces shareholder approval in connection with the proposed acquisition of Acreage & provides update on American hemp and CBD operations

    SMITHS FALLS, ON , June 19, 2019 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (WEED.TO) (CGC) is pleased to announce that, at a special meeting of the Company's shareholders (the "Meeting") held earlier today, the Company's shareholders voted overwhelmingly in favour of the resolution (the "Canopy Shareholder Resolution") approving the issuance of common shares of Canopy Growth and certain amendments to certain outstanding Company warrants in connection with the Company's previously announced proposed acquisition (the "Transaction") of Acreage Holdings, Inc. ("Acreage").

  • GlobeNewswire2 days ago

    CURE Pharmaceutical and Canopy Growth to Produce CBD Oral Thin Films

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it is collaborating with Canopy Growth Corporation (WEED.TO) (CGC), (“Canopy”) to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm™ technology for global distribution. “This collaboration builds on our licensing agreement with Canopy and accelerates product commercialization,” said Rob Davidson, CEO of CURE Pharmaceutical. CURE is registered with the U.S. Drug Enforcement Agency (DEA) to develop and manufacture cannabis-derived and synthetic cannabinoid-based products using its CUREfilm technology at its facility in Oxnard, Calif. With CUREfilm, the delivery of cannabinoids is easier and more effective as it offers increased bioavailability, ease and precision of dosing and greater palatability.

  • PR Newswire4 days ago

    Canopy Growth Provides Update on International Operations and Activities

    SMITHS FALLS, Ontario, June 17, 2019 /PRNewswire/ -- Canopy Growth Corporation ("Canopy Growth" or the "Company") (WEED.TO)(CGC) is pleased to highlight recent developments that are fueling its international progress in emerging medical cannabis and CBD markets. The Company's global three-prong strategy includes a focus on building best-in-class global GMP (Good Manufacturing Practices) infrastructure, advancing clinical research programs and best-in-class education and sales programs through its Spectrum Therapeutics medical division, and launching CBD products where regulatory environments allow.

  • Canopy Growth provides update on international operations and activities
    CNW Group4 days ago

    Canopy Growth provides update on international operations and activities

    SMITHS FALLS, ON , June 17, 2019 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (WEED.TO)(CGC) is pleased to highlight recent developments that are fueling its international progress in emerging medical cannabis and CBD markets. The Company's global three-prong strategy includes a focus on building best-in-class global GMP (Good Manufacturing Practices) infrastructure, advancing clinical research programs and best-in-class education and sales programs through its Spectrum Therapeutics medical division, and launching CBD products where regulatory environments allow.

  • Canopy Growth and Acreage Holdings Remind Shareholders to Vote FOR Canopy Growth's Plan to Acquire Acreage
    PR Newswire7 days ago

    Canopy Growth and Acreage Holdings Remind Shareholders to Vote FOR Canopy Growth's Plan to Acquire Acreage

    Canopy Growth's brands, technology and know-how is anticipated to provide Acreage with a significant advantage in an increasingly competitive U.S. market and fuel Acreage's growth. Acreage shareholders will benefit from Acreage's ability to achieve its growth strategy with an anticipated reduced cost of capital based on Canopy Growth affiliation. Canopy Growth shareholders will benefit from accelerated and turnkey access to the U.S. cannabis market upon the closing of the Transaction.

  • CNW Group11 days ago

    /R E P E A T -- Canopy Growth to Announce Fourth Quarter and Fiscal Year 2019 Financial Results/

    /R E P E A T -- Canopy Growth to Announce Fourth Quarter and Fiscal Year 2019 Financial Results/

  • CNW Group14 days ago

    Canopy Growth to Announce Fourth Quarter and Fiscal Year 2019 Financial Results

    Canopy Growth to Announce Fourth Quarter and Fiscal Year 2019 Financial Results

  • PR Newswire15 days ago

    Spectrum Therapeutics Provides Update on Its Global Clinical Research Program and Unveils Pharmacovigilance

    SMITHS FALLS, Ontario, June 6, 2019 /PRNewswire/ -- Spectrum Therapeutics ("Spectrum"), the medical division of Canopy Growth Corporation (WEED.TO) (CGC) (the "Company" or "Canopy Growth") is pleased to share an update on its efforts to develop and commercialize validated cannabis medicines through clinical trials. With a highly experienced scientific team and the resources needed to conduct robust clinical trials, Spectrum Therapeutics is pursuing research to introduce products for the therapeutic areas of pain, mood and sleep and to gain access to new markets independent of medical cannabis laws.

  • PR Newswire16 days ago

    Spectrum Therapeutics provides update on its global clinical research program and unveils pharmacovigilance program

    SMITHS FALLS, ON, June 5, 2019 /PRNewswire/ - Spectrum Therapeutics ("Spectrum"), the medical division of Canopy Growth Corporation (WEED.TO) (CGC) (the "Company" or "Canopy Growth") is pleased to share an update on its efforts to develop and commercialize validated cannabis medicines through clinical trials. With a highly experienced scientific team and the resources needed to conduct robust clinical trials, Spectrum Therapeutics is pursuing research to introduce products for the therapeutic areas of pain, mood and sleep and to gain access to new markets independent of medical cannabis laws.

  • /R E P E A T -- Meet Your New Neighbour: Tweed! Tweed Brings Its Unique Brand of Cannabis and Conversation to Saskatoon, SK/
    CNW Group22 days ago

    /R E P E A T -- Meet Your New Neighbour: Tweed! Tweed Brings Its Unique Brand of Cannabis and Conversation to Saskatoon, SK/

    SASKATOON , May 29, 2019 /CNW/ - Tweed, Canada's top cannabis producer, opened its first store in Saskatoon on May 17th and is excited to host the grand opening this Friday, May 31st . Recreational cannabis is new to many consumers, but we've been pioneers as a medical producer for years.

  • Meet Your New Neighbour: Tweed! Tweed Brings Its Unique Brand of Cannabis and Conversation to Saskatoon, SK
    CNW Group22 days ago

    Meet Your New Neighbour: Tweed! Tweed Brings Its Unique Brand of Cannabis and Conversation to Saskatoon, SK

    SASKATOON , May 29, 2019 /CNW/ - Tweed, Canada's top cannabis producer, opened its first store in Saskatoon on May 17th and is excited to host the grand opening this Friday, May 31st . Recreational cannabis is new to many consumers, but we've been pioneers as a medical producer for years.

  • CNW Group24 days ago

    Canopy Growth collaborates with Parent Action on Drugs to launch digital cannabis education tools

    SMITHS FALLS, ON and TORONTO , May 28, 2019 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (WEED.TO) (CGC) is pleased to announce the next phase in its partnership with Parent Action on Drugs ("PAD") and Canadian Students for Sensible Drug Policy ("CSSDP") which will see PAD launch two new digital tools to help youth along with their parents, adult caregivers, and influencers, on how to make responsible decisions about cannabis use. This tool helps parents structure conversations with their pre-teens about cannabis to inform and prevent early use, associated with a number of negative short and long-term outcomes. Through activities like charades, quiz questions, and "what would you do?" scenarios, chatbot users learn age-appropriate evidence-based information about cannabis, its effects, the law, risks to youth during brain development, and reasons youth consume or not.

  • PR Newswire24 days ago

    Canopy Growth subsidiary and Canopy Rivers portfolio company Vert Mirabel now fully licensed by Health Canada

    MIRABEL, QC, May 28, 2019 /PRNewswire/ - Les Serres Vert Cannabis Inc. ("Vert Mirabel"), a subsidiary of Canopy Growth Corporation (WEED.TO) (CGC) ("Canopy Growth") and a portfolio company of Canopy Rivers Inc. (RIV.V) (CNPOF) ("Canopy Rivers") has received its final cultivation licence from Health Canada. All 700,000 sq. ft. of operating space at Vert Mirabel is now licensed for cannabis production. Vert Mirabel was established in December 2017 between Canopy Growth, Canopy Rivers, and Les Serres Stéphane Bertrand ("Bertrand"). "We are thrilled that the operational infrastructure at Vert Mirabel is now fully online with over 500,000 sq. ft. already in production," said Olivier Dufourmantelle, Chief Operating Officer, Canopy Rivers.